Literature DB >> 15692422

[Retrospectively detectable carcinomas: review of the literature].

B Boyer1, L Hauret, R Bellaiche, C Gräf, B Bourcier, G Fichet.   

Abstract

Retrospectively visible cancers are defined as interval cancers or screen-detected cancers (missed cancers) which are judged visible on prior screening mammogram. There are two kinds of retrospectively visible cancers: "actionable" cancers and nonspecific findings that do not warrant recall in normal practice. Nonspecific findings are twice more frequent than actionable cancers. The rate of missed breast cancers in screening is estimated at 25% (13-41%). Missed breast cancers are masses or calcifications. Masses are twice more frequent than calcifications. Missed breast cancers result from detection errors (location in retroglandular region or at the edge of glandular tissue, architectural distorsion) and interpretation errors (findings judged as benign). Detection errors could be limited by double reading and CAD, interpretation errors by better knowledge of BIRADS classification which needs specific training.

Entities:  

Mesh:

Year:  2004        PMID: 15692422     DOI: 10.1016/s0221-0363(04)97784-0

Source DB:  PubMed          Journal:  J Radiol        ISSN: 0221-0363


  4 in total

1.  Imaging studies for the early detection of breast cancer.

Authors:  Sylvia H Heywang-Köbrunner; Ingrid Schreer; Walter Heindel; Alexander Katalinic
Journal:  Dtsch Arztebl Int       Date:  2008-08-04       Impact factor: 5.594

2.  What do experts look at and what do experts find when reading mammograms?

Authors:  Jeremy M Wolfe; Chia-Chien Wu; Jonathan Li; Sneha B Suresh
Journal:  J Med Imaging (Bellingham)       Date:  2021-07-13

Review 3.  Eye Movements in Medical Image Perception: A Selective Review of Past, Present and Future.

Authors:  Chia-Chien Wu; Jeremy M Wolfe
Journal:  Vision (Basel)       Date:  2019-06-20

4.  If you don't find it often, you often don't find it: why some cancers are missed in breast cancer screening.

Authors:  Karla K Evans; Robyn L Birdwell; Jeremy M Wolfe
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.